← Human Trials & Peer-Reviewed Studies
Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
Plain-language guide to PMID 33464336 (2021): randomized controlled trial of Angiotensin II in 659 patients.
Key Facts
- PMID
- 33464336
- Journal
- JAMA
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Lopes RD et al. (34 authors)
- DOI
- 10.1001/jama.2020.25864
- Registered trial
- NCT04364893
What This Study Did, in Plain Language
What Was Tested
Researchers studied Angiotensin II in this randomized controlled trial publication.
To determine whether discontinuation compared with continuation of ACEIs or ARBs changed the number of days alive and out of the hospital through 30 days.
Why It Was Studied
It is unknown whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) have a positive, neutral, or negative effect on clinical outcomes in patients with coronavirus disease 2019 (COVID-19).
Who Took Part
The abstract describes 659 patients taking part.
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
A randomized clinical trial of 659 patients hospitalized in Brazil with mild to moderate COVID-19 who were taking ACEIs or ARBs prior to hospitalization (enrolled: April 9-June 26, 2020; final follow-up: July 26, 2020).
How the Study Was Run
In design terms this was a randomized study.
The patients were allocated by chance, so the Angiotensin II group and the comparison group should start out alike.
Discontinuation (n = 334) or continuation (n = 325) of ACEIs or ARBs.
What Was Measured
It is unknown whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) have a positive, neutral, or negative effect on clinical outcomes in patients with coronavirus disease 2019 (COVID-19).
Topics PubMed links to this paper include Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, COVID-19, Disease Progression, Heart Failure, Hospitalization and Myocardial Infarction.
What This Means in Plain Language
The paper is a randomized study of Angiotensin II in 659 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2021 (JAMA), a journal based in United States.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.